Dr. Bupathi discusses JAVELIN Bladder 100 trial of maintenance avelumab

Manojkumar Bupathi, MD, MS, a medical oncologist at Rocky Mountain Cancer Centers, highlights the significance of the phase 3 JAVELIN Bladder 100 trial, in which patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy were randomized to best supportive care (BSC) with or without maintenance avelumab (Bavencio).

The FDA approved avelumab in this setting based on the JAVELIN Bladder 100 results, which showed a median overall survival of 21.4 months with avelumab plus BSC compared with 14.3 months with BSC alone. This 7.1-month benefit translated to a 31% reduction in the risk of death (HR, 0.69; 95% CI, 0.56-0.86; P <.001).